Genfit S.A. (OTCMKTS:GNFTF) Sees Large Drop in Short Interest

Genfit S.A. (OTCMKTS:GNFTF) was the recipient of a large decrease in short interest during the month of December. As of December 15th, there was short interest totaling 3,250 shares, a decrease of 37.5% from the November 30th total of 5,200 shares. Based on an average daily trading volume, of 0 shares, the short-interest ratio is presently ∞ days. Based on an average daily trading volume, of 0 shares, the short-interest ratio is presently ∞ days.

Genfit Price Performance

GNFTF opened at $6.07 on Tuesday. The business’s fifty day simple moving average is $4.12 and its 200 day simple moving average is $3.81. Genfit has a 52 week low of $4.14 and a 52 week high of $6.07.

About Genfit

Genfit is a clinical‐stage biopharmaceutical company headquartered in Lille, France, specializing in the development of innovative therapies and diagnostics for liver and metabolic diseases. The company’s research and development efforts are primarily focused on non‐alcoholic steatohepatitis (NASH), a progressive liver disorder with significant unmet medical needs. Genfit’s lead therapeutic candidate, elafibranor, is designed to target key pathways involved in inflammation, fibrosis and lipid metabolism, positioning it as a potential treatment for patients with NASH and associated metabolic complications.

In addition to its therapeutic pipeline, Genfit has established a diagnostic arm centered on NIS4®, a proprietary blood‐based test that leverages transcriptomic biomarkers to enable earlier and more accurate detection of liver fibrosis in patients at risk for NASH.